FDA approves Remdesivir for COVID-19 despite WHO study showing no benefit

Edited by Ed Newman
2020-10-24 11:43:48

Pinterest
Telegram
Linkedin
WhatsApp

FDA approves Remdesivir for COVID-19 despite WHO study showing no benefit. (Photo: AP)

Washington, October 24 (RHC)-- The U.S. Food and Drug Administration has approved Remdesivir as the first COVID-19 treatment in the United States. 

Some studies have shown the antiviral drug may reduce the number of days COVID-19 patients are hospitalized, although a large World Health Organization study published last week found Remdesivir fails to prevent deaths among COVID-19 patients.



Commentaries


MAKE A COMMENT
All fields required
NOT TO BE PUBLISHED
captcha challenge
up